… might be potential candidates for COVID-19 therapeutics. This … leukotrienes in COVID-19,
and the rational for the use of the leukotriene receptor antagonist montelukast as a COVID-19 …

… occurrence of COVID-19 cases [18] and lung function deterioration [19] among the montelukast-…
patients were significantly reduced as compared to the nonmontelukast group [18, 19]. …

… to elucidate the potential role of leukotrienes (LTs) in the … role of LT pathway receptor
antagonists and inhibitors in Covid-19 … ”, “leukotriene receptor antagonist OR leukotriene synthesis …

… (cysLT) receptor antagonist with anti-inflammatory … leukotriene receptors and activate the
NF-κB pathway via the NF-κB transcription factor. Montelukast is a cysLT receptor 1 antagonist …

… a 5-lipoxygenase inhibitor (zileuton) and an LTRA (montelukast). Montelukast has been in
… We suggest a treatment paradigm with two leukotriene modifiers zileuton CR/montelukast in …

… , and montelukast, a leukotriene receptor antagonist, exhibit … to treat the symptoms of
COVID-19. Clinical data to date with … many of the aspects of ‘Long COVID,’ thereby cost effectively …

… of COVID-19, but few approaches have been proven efficacious. Because leukotriene receptor
antagonists, such as montelukast … with montelukast could be used to treat COVID-19. The …

… COVID‐19 is at least partially caused by mast cell activation, and leukotriene receptor antagonists
like montelukast … into the role of montelukast in SARS‐CoV‐2 prevention or COVID‐19 …

… could also potentially serve as a treatment for COVID-19 [… to review the pleiotropic effects of
montelukast and to explore how … potential role for a selective leukotriene receptor antagonist. …

… Leukotriene receptor antagonists, such as montelukast, have … lavage of COVID-19 patients,
and montelukast, in addition to its … platelet activation characteristic of COVID-19 syndrome. In …